首页 > 最新文献

Heart Failure Reviews最新文献

英文 中文
New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy. 从心肌炎和炎症性心肌病的细胞景观变化中获得新见解。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-06-19 DOI: 10.1007/s10741-024-10406-w
Weiteng Wang, Hao Jia, Xiumeng Hua, Jiangping Song

Advances in the etiological classification of myocarditis and inflammatory cardiomyopathy (ICM) have reached a consensus. However, the mechanism of myocarditis/ICM remains unclear, which affects the development of treatment and the improvement of outcome. Cellular transcription and metabolic reprogramming, and the interactions between cardiomyocytes and non-cardiomyocytes, such as the immune cells, contribute to the process of myocarditis/ICM. Recent efforts have been made by multi-omics techniques, particularly in single-cell RNA sequencing, to gain a better understanding of the cellular landscape alteration occurring in disease during the progression. This article aims to provide a comprehensive overview of the latest studies in myocarditis/ICM, particularly as revealed by single-cell sequencing.

心肌炎和炎症性心肌病(ICM)的病因分类取得了进展,并已达成共识。然而,心肌炎/炎症性心肌病的发病机制仍不清楚,这影响了治疗的发展和疗效的改善。细胞转录和代谢重编程,以及心肌细胞与非心肌细胞(如免疫细胞)之间的相互作用,都是心肌炎/心肌病发生的原因。近年来,多组学技术,尤其是单细胞 RNA 测序技术的应用,使人们对疾病进展过程中发生的细胞景观变化有了更深入的了解。本文旨在全面概述有关心肌炎/心肌梗死的最新研究,尤其是单细胞测序所揭示的内容。
{"title":"New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy.","authors":"Weiteng Wang, Hao Jia, Xiumeng Hua, Jiangping Song","doi":"10.1007/s10741-024-10406-w","DOIUrl":"10.1007/s10741-024-10406-w","url":null,"abstract":"<p><p>Advances in the etiological classification of myocarditis and inflammatory cardiomyopathy (ICM) have reached a consensus. However, the mechanism of myocarditis/ICM remains unclear, which affects the development of treatment and the improvement of outcome. Cellular transcription and metabolic reprogramming, and the interactions between cardiomyocytes and non-cardiomyocytes, such as the immune cells, contribute to the process of myocarditis/ICM. Recent efforts have been made by multi-omics techniques, particularly in single-cell RNA sequencing, to gain a better understanding of the cellular landscape alteration occurring in disease during the progression. This article aims to provide a comprehensive overview of the latest studies in myocarditis/ICM, particularly as revealed by single-cell sequencing.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"883-907"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol. PCSK9 在心力衰竭和其他心血管疾病中的作用--除了对低密度脂蛋白胆固醇的影响之外的作用机制。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1007/s10741-024-10409-7
Mieczysław Dutka, Karolina Zimmer, Michał Ćwiertnia, Tomasz Ilczak, Rafał Bobiński

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a protein that regulates low-density lipoprotein (LDL) cholesterol metabolism by binding to the hepatic LDL receptor (LDLR), ultimately leading to its lysosomal degradation and an increase in LDL cholesterol (LDLc) levels. Treatment strategies have been developed based on blocking PCSK9 with specific antibodies (alirocumab, evolocumab) and on blocking its production with small regulatory RNA (siRNA) (inclisiran). Clinical trials evaluating these drugs have confirmed their high efficacy in reducing serum LDLc levels and improving the prognosis in patients with atherosclerotic cardiovascular diseases. Most studies have focused on the action of PCSK9 on LDLRs and the subsequent increase in LDLc concentrations. Increasing evidence suggests that the adverse cardiovascular effects of PCSK9, particularly its atherosclerotic effects on the vascular wall, may also result from mechanisms independent of its effects on lipid metabolism. PCSK9 induces the expression of pro-inflammatory cytokines contributing to inflammation within the vascular wall and promotes apoptosis, pyroptosis, and ferroptosis of cardiomyocytes and is thus involved in the development and progression of heart failure. The elimination of PCSK9 may, therefore, not only be a treatment for hypercholesterolaemia but also for atherosclerosis and other cardiovascular diseases. The mechanisms of action of PCSK9 in the cardiovascular system are not yet fully understood. This article reviews the current understanding of the mechanisms of PCSK9 action in the cardiovascular system and its contribution to cardiovascular diseases. Knowledge of these mechanisms may contribute to the wider use of PCSK9 inhibitors in the treatment of cardiovascular diseases.

Proprotein convertase subtilisin/kexin type-9 (PCSK9)是一种通过与肝脏低密度脂蛋白受体(LDLR)结合来调节低密度脂蛋白(LDL)胆固醇代谢的蛋白质,最终导致其溶酶体降解和低密度脂蛋白胆固醇(LDLc)水平升高。目前已开发出通过特异性抗体(alirocumab、evolocumab)阻断 PCSK9 和通过小调控 RNA(siRNA)(inclisiran)阻断 PCSK9 生成的治疗策略。评估这些药物的临床试验证实,它们在降低动脉粥样硬化性心血管疾病患者血清低密度脂蛋白胆固醇(LDLc)水平和改善预后方面具有很高的疗效。大多数研究侧重于 PCSK9 对 LDLRs 的作用以及随后 LDLc 浓度的增加。越来越多的证据表明,PCSK9 对心血管的不良影响,尤其是对血管壁的动脉粥样硬化影响,也可能来自于其对脂质代谢影响之外的机制。PCSK9 可诱导促炎细胞因子的表达,导致血管壁发炎,并促进心肌细胞凋亡、热凋亡和铁凋亡,从而参与心力衰竭的发生和发展。因此,消除 PCSK9 不仅可以治疗高胆固醇血症,还可以治疗动脉粥样硬化和其他心血管疾病。PCSK9在心血管系统中的作用机制尚未完全明了。本文回顾了目前对 PCSK9 在心血管系统中的作用机制及其对心血管疾病的影响的认识。对这些机制的了解可能有助于在治疗心血管疾病时更广泛地使用 PCSK9 抑制剂。
{"title":"The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol.","authors":"Mieczysław Dutka, Karolina Zimmer, Michał Ćwiertnia, Tomasz Ilczak, Rafał Bobiński","doi":"10.1007/s10741-024-10409-7","DOIUrl":"10.1007/s10741-024-10409-7","url":null,"abstract":"<p><p>Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a protein that regulates low-density lipoprotein (LDL) cholesterol metabolism by binding to the hepatic LDL receptor (LDLR), ultimately leading to its lysosomal degradation and an increase in LDL cholesterol (LDLc) levels. Treatment strategies have been developed based on blocking PCSK9 with specific antibodies (alirocumab, evolocumab) and on blocking its production with small regulatory RNA (siRNA) (inclisiran). Clinical trials evaluating these drugs have confirmed their high efficacy in reducing serum LDLc levels and improving the prognosis in patients with atherosclerotic cardiovascular diseases. Most studies have focused on the action of PCSK9 on LDLRs and the subsequent increase in LDLc concentrations. Increasing evidence suggests that the adverse cardiovascular effects of PCSK9, particularly its atherosclerotic effects on the vascular wall, may also result from mechanisms independent of its effects on lipid metabolism. PCSK9 induces the expression of pro-inflammatory cytokines contributing to inflammation within the vascular wall and promotes apoptosis, pyroptosis, and ferroptosis of cardiomyocytes and is thus involved in the development and progression of heart failure. The elimination of PCSK9 may, therefore, not only be a treatment for hypercholesterolaemia but also for atherosclerosis and other cardiovascular diseases. The mechanisms of action of PCSK9 in the cardiovascular system are not yet fully understood. This article reviews the current understanding of the mechanisms of PCSK9 action in the cardiovascular system and its contribution to cardiovascular diseases. Knowledge of these mechanisms may contribute to the wider use of PCSK9 inhibitors in the treatment of cardiovascular diseases.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"917-937"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal function in PUSH-AHF: a summary of newly released data from the 2024 Annual Congress of the Heart Failure Association of the ESC. PUSH-AHF中的肾功能:ESC心力衰竭协会2024年年会最新发布的数据摘要。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI: 10.1007/s10741-024-10411-z
Alexander Aaron Yacob, Kelsey M Flint

The Pragmatic Urinary Sodium-based algoritHm in Acute Heart Failure (PUSH-AHF) study, published in August of 2023, was the first randomized clinical trial to compare natriuresis-guided decongestion (based on spot urinary sodium measurement) to standard of care in patients with acute heart failure with congestion receiving loop diuretic therapy. Based on results from their trial, the authors concluded that natriuresis-guided loop diuretic treatment was safe and improved natriuresis and diuresis without impacting long-term clinical outcomes. The original PUSH-AHF trial included limited information about renal outcomes and left clinicians with important questions about how natriuresis-guided decongestion might affect their patients' renal function. On May 12, 2024, however, at the 2024 Annual Congress of the HFA-ESC, Dr. Kevin Damman provided an in-depth exploration of renal outcomes from the trial when he presented a pre-specified, secondary analysis, renal function in the PUSH-AHF trial. This review puts the sub-study findings into context by considering the history of the original trial from which they came from and explaining the need for a close study of its renal outcomes particularly. It highlights the potential impact of renal function in PUSH-AHF on clinical practice and future directions that should be considered by the cardiology research community.

2023 年 8 月发表的 "基于尿钠的急性心力衰竭实用算法(PUSH-AHF)"研究是第一项随机临床试验,该试验比较了接受襻利尿剂治疗的急性心力衰竭充血患者在利尿剂指导下的减充血(基于定点尿钠测量)和标准护理。根据试验结果,作者得出结论:利尿剂引导下的襻利尿剂治疗是安全的,可改善利尿和利尿效果,且不会影响长期临床疗效。最初的 PUSH-AHF 试验中有关肾脏预后的信息有限,临床医生对于纳尿引导下的减压治疗可能会如何影响患者的肾功能还存在重要疑问。然而,在 2024 年 5 月 12 日举行的 HFA-ESC 2024 年年会上,凯文-达曼(Kevin Damman)博士发表了一份预先指定的二次分析报告《PUSH-AHF 试验中的肾功能》,对该试验的肾功能结果进行了深入探讨。这篇综述介绍了次级研究结果的来龙去脉,考虑了这些结果所来源的原始试验的历史,并解释了对其肾脏结果进行仔细研究的必要性。它强调了 PUSH-AHF 中肾功能对临床实践的潜在影响以及心脏病学研究界应考虑的未来方向。
{"title":"Renal function in PUSH-AHF: a summary of newly released data from the 2024 Annual Congress of the Heart Failure Association of the ESC.","authors":"Alexander Aaron Yacob, Kelsey M Flint","doi":"10.1007/s10741-024-10411-z","DOIUrl":"10.1007/s10741-024-10411-z","url":null,"abstract":"<p><p>The Pragmatic Urinary Sodium-based algoritHm in Acute Heart Failure (PUSH-AHF) study, published in August of 2023, was the first randomized clinical trial to compare natriuresis-guided decongestion (based on spot urinary sodium measurement) to standard of care in patients with acute heart failure with congestion receiving loop diuretic therapy. Based on results from their trial, the authors concluded that natriuresis-guided loop diuretic treatment was safe and improved natriuresis and diuresis without impacting long-term clinical outcomes. The original PUSH-AHF trial included limited information about renal outcomes and left clinicians with important questions about how natriuresis-guided decongestion might affect their patients' renal function. On May 12, 2024, however, at the 2024 Annual Congress of the HFA-ESC, Dr. Kevin Damman provided an in-depth exploration of renal outcomes from the trial when he presented a pre-specified, secondary analysis, renal function in the PUSH-AHF trial. This review puts the sub-study findings into context by considering the history of the original trial from which they came from and explaining the need for a close study of its renal outcomes particularly. It highlights the potential impact of renal function in PUSH-AHF on clinical practice and future directions that should be considered by the cardiology research community.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"945-948"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
STEP HFpEF DM: a sweet sequel. STEP HFpEF DM:甜蜜续集。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1007/s10741-024-10408-8
Josephine Harrington
{"title":"STEP HFpEF DM: a sweet sequel.","authors":"Josephine Harrington","doi":"10.1007/s10741-024-10408-8","DOIUrl":"10.1007/s10741-024-10408-8","url":null,"abstract":"","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"913-915"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biosensors with left ventricular assist devices. 带有左心室辅助装置的生物传感器。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-06-28 DOI: 10.1007/s10741-024-10413-x
Mahmoud Abbassy, Muhammad Zain Ali, Riya Manas Sharma, Yohan Porus Irani, Adil Dahlan, Maimoona Azhar, Nadeem Aslam, Babar Hasan, Aamir Hameed

Heart failure imposes a significant global health burden, standing as a primary contributor to mortality. Various indicators and physiological shifts within the body may hint at distinct cardiac conditions. Specific biosensors have the capability to identify these changes. Integrating or embedding these biosensors into mechanical circulatory support devices (MCSDs), such as left ventricular assist devices (LVADs), becomes crucial for monitoring alterations in biochemical and physiological factors subsequent to an MCSD implantation. Detecting abnormal changes early in the course of disease progression will allow for improved patient outcomes and prognosis following an MCSD implantation. The aim of this review is to explore the available biosensors that may be coupled or implanted alongside LVADs to monitor biomarkers and changes in physiological parameters. Different fabrication materials for the biosensors are discussed, including their advantages and disadvantages. This review also examines the feasibility of integrating feedback control mechanisms into LVAD systems using data from the biosensors. Challenges facing this emerging technology and future directions for research and development are outlined as well. The overarching goal is to provide an overview of how implanted biosensors may improve the performance and outcomes of LVADs through continuous monitoring and closed-loop control.

心力衰竭给全球健康带来沉重负担,是导致死亡的主要因素。人体内的各种指标和生理变化可能暗示着不同的心脏状况。特定的生物传感器能够识别这些变化。将这些生物传感器集成或嵌入机械循环支持装置(MCSD),如左心室辅助装置(LVAD),对于监测 MCSD 植入后生化和生理因素的变化至关重要。在疾病进展的早期发现异常变化将有助于改善植入 MCSD 后患者的预后。本综述旨在探讨现有的生物传感器,这些传感器可与 LVAD 相结合或植入 LVAD,以监测生物标志物和生理参数的变化。文中讨论了生物传感器的不同制造材料,包括其优缺点。本综述还探讨了利用生物传感器的数据将反馈控制机制整合到 LVAD 系统中的可行性。此外,还概述了这一新兴技术所面临的挑战以及未来的研发方向。总体目标是概述植入式生物传感器如何通过持续监测和闭环控制改善 LVAD 的性能和效果。
{"title":"Biosensors with left ventricular assist devices.","authors":"Mahmoud Abbassy, Muhammad Zain Ali, Riya Manas Sharma, Yohan Porus Irani, Adil Dahlan, Maimoona Azhar, Nadeem Aslam, Babar Hasan, Aamir Hameed","doi":"10.1007/s10741-024-10413-x","DOIUrl":"10.1007/s10741-024-10413-x","url":null,"abstract":"<p><p>Heart failure imposes a significant global health burden, standing as a primary contributor to mortality. Various indicators and physiological shifts within the body may hint at distinct cardiac conditions. Specific biosensors have the capability to identify these changes. Integrating or embedding these biosensors into mechanical circulatory support devices (MCSDs), such as left ventricular assist devices (LVADs), becomes crucial for monitoring alterations in biochemical and physiological factors subsequent to an MCSD implantation. Detecting abnormal changes early in the course of disease progression will allow for improved patient outcomes and prognosis following an MCSD implantation. The aim of this review is to explore the available biosensors that may be coupled or implanted alongside LVADs to monitor biomarkers and changes in physiological parameters. Different fabrication materials for the biosensors are discussed, including their advantages and disadvantages. This review also examines the feasibility of integrating feedback control mechanisms into LVAD systems using data from the biosensors. Challenges facing this emerging technology and future directions for research and development are outlined as well. The overarching goal is to provide an overview of how implanted biosensors may improve the performance and outcomes of LVADs through continuous monitoring and closed-loop control.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"957-967"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nexilin in cardiomyopathy: unveiling its diverse roles with special focus on endocardial fibroelastosis. 心肌病中的 Nexilin:揭示其多种作用,特别关注心内膜纤维细胞增生。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1007/s10741-024-10416-8
Mahsa Rahimzadeh, Stephanie Tennstedt, Zouhair Aherrahrou

Cardiac disorders exhibit considerable heterogeneity, and understanding their genetic foundations is crucial for their diagnosis and treatment. Recent genetic analyses involving a growing number of participants have uncovered novel mutations within both coding and non-coding regions of DNA, contributing to the onset of cardiac conditions. The NEXN gene, encoding the Nexilin protein, an actin filament-binding protein, is integral to normal cardiac function. Mutations in this gene have been linked to cardiomyopathies, cardiovascular disorders, and sudden deaths. Heterozygous or homozygous variants of the NEXN gene are associated with the development of endocardial fibroelastosis (EFE), a rare cardiac condition characterized by excessive collagen and elastin deposition in the left ventricular endocardium predominantly affecting infants and young children. EFE occurs both primary and secondary to other conditions and often leads to unfavorable prognoses and outcomes. This review explores the role of NEXN genetic variants in cardiovascular disorders, particularly EFE, revealing that functional mutations are not clustered in a specific domain of Nexilin based on the cardiac disorder phenotype. Our review underscores the importance of understanding genetic mutations for the diagnosis and treatment of cardiac conditions.

心脏疾病具有很大的异质性,了解其遗传基础对诊断和治疗至关重要。最近,越来越多的参与者参与了基因分析,发现了 DNA 编码和非编码区域内的新型突变,这些突变导致了心脏疾病的发生。编码肌动蛋白丝结合蛋白 Nexilin 蛋白的 NEXN 基因是正常心脏功能不可或缺的组成部分。该基因突变与心肌病、心血管疾病和猝死有关。NEXN 基因的杂合或同源变异与心内膜纤维细胞增生症(EFE)的发生有关,这是一种罕见的心脏疾病,其特点是左心室心内膜胶原蛋白和弹性蛋白沉积过多,主要影响婴幼儿。EFE 既可原发,也可继发于其他疾病,通常会导致不良的预后和结局。本综述探讨了 NEXN 基因变异在心血管疾病(尤其是 EFE)中的作用,揭示了功能性突变并不是根据心脏疾病表型聚集在 Nexilin 的特定领域。我们的综述强调了了解基因突变对诊断和治疗心脏疾病的重要性。
{"title":"Nexilin in cardiomyopathy: unveiling its diverse roles with special focus on endocardial fibroelastosis.","authors":"Mahsa Rahimzadeh, Stephanie Tennstedt, Zouhair Aherrahrou","doi":"10.1007/s10741-024-10416-8","DOIUrl":"10.1007/s10741-024-10416-8","url":null,"abstract":"<p><p>Cardiac disorders exhibit considerable heterogeneity, and understanding their genetic foundations is crucial for their diagnosis and treatment. Recent genetic analyses involving a growing number of participants have uncovered novel mutations within both coding and non-coding regions of DNA, contributing to the onset of cardiac conditions. The NEXN gene, encoding the Nexilin protein, an actin filament-binding protein, is integral to normal cardiac function. Mutations in this gene have been linked to cardiomyopathies, cardiovascular disorders, and sudden deaths. Heterozygous or homozygous variants of the NEXN gene are associated with the development of endocardial fibroelastosis (EFE), a rare cardiac condition characterized by excessive collagen and elastin deposition in the left ventricular endocardium predominantly affecting infants and young children. EFE occurs both primary and secondary to other conditions and often leads to unfavorable prognoses and outcomes. This review explores the role of NEXN genetic variants in cardiovascular disorders, particularly EFE, revealing that functional mutations are not clustered in a specific domain of Nexilin based on the cardiac disorder phenotype. Our review underscores the importance of understanding genetic mutations for the diagnosis and treatment of cardiac conditions.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1025-1037"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The significance of the apelinergic system in doxorubicin-induced cardiotoxicity. 凋亡素能系统在多柔比星诱导的心脏毒性中的重要作用
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-07-11 DOI: 10.1007/s10741-024-10414-w
Katarzyna Matusik, Katarzyna Kamińska, Aleksandra Sobiborowicz-Sadowska, Hubert Borzuta, Kasper Buczma, Agnieszka Cudnoch-Jędrzejewska

Cancer is the leading cause of death worldwide, and the number of cancer-related deaths is expected to increase. Common types of cancer include skin, breast, lung, prostate, and colorectal cancers. While clinical research has improved cancer therapies, these treatments often come with significant side effects such as chronic fatigue, hair loss, and nausea. In addition, cancer treatments can cause long-term cardiovascular complications. Doxorubicin (DOX) therapy is one example, which can lead to decreased left ventricle (LV) echocardiography (ECHO) parameters, increased oxidative stress in cellular level, and even cardiac fibrosis. The apelinergic system, specifically apelin and its receptor, together, has shown properties that could potentially protect the heart and mitigate the damages caused by DOX anti-cancer treatment. Studies have suggested that stimulating the apelinergic system may have therapeutic benefits for heart damage induced by DOX. Further research in chronic preclinical models is needed to confirm this hypothesis and understand the mechanism of action for the apelinergic system. This review aims to collect and present data on the effects of the apelinergic system on doxorubicin-induced cardiotoxicity.

癌症是导致全球死亡的主要原因,预计与癌症相关的死亡人数还会增加。常见的癌症类型包括皮肤癌、乳腺癌、肺癌、前列腺癌和结肠直肠癌。虽然临床研究已经改进了癌症疗法,但这些疗法往往会带来严重的副作用,如慢性疲劳、脱发和恶心。此外,癌症治疗还会引起长期的心血管并发症。多柔比星(DOX)疗法就是一个例子,它会导致左心室(LV)超声心动图(ECHO)参数下降、细胞水平氧化应激增加,甚至心脏纤维化。凋亡素能系统,特别是凋亡素及其受体,具有潜在保护心脏和减轻 DOX 抗癌治疗所造成损害的特性。研究表明,刺激凋亡素能系统可能对 DOX 引起的心脏损伤有治疗作用。要证实这一假设并了解凋亡素能系统的作用机制,还需要在慢性临床前模型中开展进一步研究。本综述旨在收集和介绍有关凋亡素能系统对多柔比星诱导的心脏毒性的影响的数据。
{"title":"The significance of the apelinergic system in doxorubicin-induced cardiotoxicity.","authors":"Katarzyna Matusik, Katarzyna Kamińska, Aleksandra Sobiborowicz-Sadowska, Hubert Borzuta, Kasper Buczma, Agnieszka Cudnoch-Jędrzejewska","doi":"10.1007/s10741-024-10414-w","DOIUrl":"10.1007/s10741-024-10414-w","url":null,"abstract":"<p><p>Cancer is the leading cause of death worldwide, and the number of cancer-related deaths is expected to increase. Common types of cancer include skin, breast, lung, prostate, and colorectal cancers. While clinical research has improved cancer therapies, these treatments often come with significant side effects such as chronic fatigue, hair loss, and nausea. In addition, cancer treatments can cause long-term cardiovascular complications. Doxorubicin (DOX) therapy is one example, which can lead to decreased left ventricle (LV) echocardiography (ECHO) parameters, increased oxidative stress in cellular level, and even cardiac fibrosis. The apelinergic system, specifically apelin and its receptor, together, has shown properties that could potentially protect the heart and mitigate the damages caused by DOX anti-cancer treatment. Studies have suggested that stimulating the apelinergic system may have therapeutic benefits for heart damage induced by DOX. Further research in chronic preclinical models is needed to confirm this hypothesis and understand the mechanism of action for the apelinergic system. This review aims to collect and present data on the effects of the apelinergic system on doxorubicin-induced cardiotoxicity.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"969-988"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ex vivo heart perfusion: an updated systematic review. 体外心脏灌注:最新系统综述。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI: 10.1007/s10741-024-10420-y
Nicola Pradegan, Luigi Di Pasquale, Dario Di Perna, Michele Gallo, Giovanni Lucertini, Marco Gemelli, Thomas Beyerle, Mark S Slaughter, Gino Gerosa

Due to the discrepancy between patients awaiting a heart transplant and the availability of donor hearts, strategies to expand the donor pool and improve the transplant's success are crucial. This review aims to summarize current knowledge on the ex vivo heart preservation (EVHP) experience as an alternative to standard cold static storage (CSS). EVHP techniques can improve the preservation of the donor's heart before transplantation and allow for pre-transplant organ evaluation.

由于等待心脏移植的患者与可获得的供体心脏之间存在差异,因此扩大供体库和提高移植成功率的策略至关重要。本综述旨在总结目前有关体外心脏保存(EVHP)经验的知识,以替代标准的冷冻静态保存(CSS)。EVHP技术可以在移植前更好地保存捐献者的心脏,并进行移植前器官评估。
{"title":"Ex vivo heart perfusion: an updated systematic review.","authors":"Nicola Pradegan, Luigi Di Pasquale, Dario Di Perna, Michele Gallo, Giovanni Lucertini, Marco Gemelli, Thomas Beyerle, Mark S Slaughter, Gino Gerosa","doi":"10.1007/s10741-024-10420-y","DOIUrl":"10.1007/s10741-024-10420-y","url":null,"abstract":"<p><p>Due to the discrepancy between patients awaiting a heart transplant and the availability of donor hearts, strategies to expand the donor pool and improve the transplant's success are crucial. This review aims to summarize current knowledge on the ex vivo heart preservation (EVHP) experience as an alternative to standard cold static storage (CSS). EVHP techniques can improve the preservation of the donor's heart before transplantation and allow for pre-transplant organ evaluation.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1079-1096"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acetazolamide therapy in patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials. 急性心力衰竭患者的乙酰唑胺治疗:随机对照试验的系统回顾和荟萃分析。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1007/s10741-024-10417-7
Tanize Louize Milbradt, Renan Yuji Ura Sudo, Marília Oberto da Silva Gobbo, Stephen Akinfenwa, Brenda Moura

Acute heart failure (AHF) often leads to unfavorable outcomes due to fluid overload. While diuretics are the cornerstone treatment, acetazolamide may enhance diuretic efficiency by reducing sodium reabsorption. We performed a systematic review and meta-analysis on the effects of acetazolamide as an add-on therapy in patients with AHF compared to diuretic therapy. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCT). A random-effects model was employed to compute mean differences and risk ratios. Statistical analysis was performed using R software. The GRADE approach was used to rate the certainty of the evidence. We included 4 RCTs with 634 patients aged 68 to 81 years. Over a mean follow-up of 3 days to 34 months, acetazolamide significantly increased diuresis (MD 899.2 mL; 95% CI 249.5 to 1549; p < 0.01) and natriuresis (MD 72.44 mmol/L; 95% CI 39.4 to 105.4; p < 0.01) after 48 h of its administration. No association was found between acetazolamide use and WRF (RR 2.4; 95% CI 0.4 to 14.2; p = 0.3) or all-cause mortality (RR 1.2; 95% CI 0.8 to 1.9; p = 0.3). Clinical decongestion was significantly higher in the intervention group (RR 1.35; 95% CI 1.09 to 1.68; p = 0.01). Acetazolamide is an effective add-on therapy in patients with AHF, increasing diuresis, natriuresis, and clinical decongestion, but it was not associated with differences in mortality.

急性心力衰竭(AHF)常因体液超负荷而导致不良后果。虽然利尿剂是治疗的基础,但乙酰唑胺可通过减少钠的重吸收来提高利尿剂的效率。我们对乙酰唑胺作为 AHF 患者的附加疗法与利尿剂疗法的效果进行了系统回顾和荟萃分析。我们在 PubMed、Embase 和 Cochrane 数据库中检索了随机对照试验 (RCT)。采用随机效应模型计算平均差异和风险比。统计分析使用 R 软件进行。采用 GRADE 方法对证据的确定性进行评分。我们纳入了 4 项 RCT 研究,共涉及 634 名年龄在 68 至 81 岁之间的患者。在平均 3 天至 34 个月的随访期间,乙酰唑胺显著增加了利尿量(MD 899.2 mL; 95% CI 249.5 至 1549; p
{"title":"Acetazolamide therapy in patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials.","authors":"Tanize Louize Milbradt, Renan Yuji Ura Sudo, Marília Oberto da Silva Gobbo, Stephen Akinfenwa, Brenda Moura","doi":"10.1007/s10741-024-10417-7","DOIUrl":"10.1007/s10741-024-10417-7","url":null,"abstract":"<p><p>Acute heart failure (AHF) often leads to unfavorable outcomes due to fluid overload. While diuretics are the cornerstone treatment, acetazolamide may enhance diuretic efficiency by reducing sodium reabsorption. We performed a systematic review and meta-analysis on the effects of acetazolamide as an add-on therapy in patients with AHF compared to diuretic therapy. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCT). A random-effects model was employed to compute mean differences and risk ratios. Statistical analysis was performed using R software. The GRADE approach was used to rate the certainty of the evidence. We included 4 RCTs with 634 patients aged 68 to 81 years. Over a mean follow-up of 3 days to 34 months, acetazolamide significantly increased diuresis (MD 899.2 mL; 95% CI 249.5 to 1549; p < 0.01) and natriuresis (MD 72.44 mmol/L; 95% CI 39.4 to 105.4; p < 0.01) after 48 h of its administration. No association was found between acetazolamide use and WRF (RR 2.4; 95% CI 0.4 to 14.2; p = 0.3) or all-cause mortality (RR 1.2; 95% CI 0.8 to 1.9; p = 0.3). Clinical decongestion was significantly higher in the intervention group (RR 1.35; 95% CI 1.09 to 1.68; p = 0.01). Acetazolamide is an effective add-on therapy in patients with AHF, increasing diuresis, natriuresis, and clinical decongestion, but it was not associated with differences in mortality.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1039-1047"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-intensity care for GDMT titration. 为 GDMT 滴定提供高强度护理。
IF 4.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 Epub Date: 2024-07-22 DOI: 10.1007/s10741-024-10419-5
Jan Biegus, Matteo Pagnesi, Beth Davison, Piotr Ponikowski, Alexander Mebazaa, Gadi Cotter

Heart failure (HF) is a systemic disease associated with a high risk of morbidity, mortality, increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic treatment strategies are necessary to mitigate these risks. In this manuscript, we emphasize the concept of high-intensity care to optimize guideline-directed medical therapy (GDMT) in HF patients. The document highlights the importance of achieving optimal recommended doses of GDMT medications, including beta-blockers, renin-angiotensin-aldosterone inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter inhibitors to improve patient outcomes, achieve effective, sustainable decongestion, and improve patient quality of life. The document also discusses potential obstacles to GDMT optimization, such as clinical inertia, physiological limitations, comorbidities, non-adherence, and frailty. Lastly, it also attempts to provide possible future scenarios of high-intensive care that could improve patient outcomes.

心力衰竭(HF)是一种全身性疾病,具有发病率高、死亡率高、住院风险增加和生活质量低的特点。因此,有必要采取有效的系统治疗策略来降低这些风险。在这份手稿中,我们强调了高强度护理的概念,以优化高血压患者的指导性医疗疗法(GDMT)。本文强调了实现 GDMT 药物最佳推荐剂量的重要性,包括β-受体阻滞剂、肾素-血管紧张素-醛固酮抑制剂、矿物质皮质激素受体拮抗剂和钠-葡萄糖共转运体抑制剂,以改善患者预后,实现有效、可持续的去充血,并提高患者的生活质量。文件还讨论了 GDMT 优化的潜在障碍,如临床惰性、生理限制、合并症、不依从性和虚弱。最后,文件还试图提供未来可能出现的高强度护理方案,以改善患者的预后。
{"title":"High-intensity care for GDMT titration.","authors":"Jan Biegus, Matteo Pagnesi, Beth Davison, Piotr Ponikowski, Alexander Mebazaa, Gadi Cotter","doi":"10.1007/s10741-024-10419-5","DOIUrl":"10.1007/s10741-024-10419-5","url":null,"abstract":"<p><p>Heart failure (HF) is a systemic disease associated with a high risk of morbidity, mortality, increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic treatment strategies are necessary to mitigate these risks. In this manuscript, we emphasize the concept of high-intensity care to optimize guideline-directed medical therapy (GDMT) in HF patients. The document highlights the importance of achieving optimal recommended doses of GDMT medications, including beta-blockers, renin-angiotensin-aldosterone inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter inhibitors to improve patient outcomes, achieve effective, sustainable decongestion, and improve patient quality of life. The document also discusses potential obstacles to GDMT optimization, such as clinical inertia, physiological limitations, comorbidities, non-adherence, and frailty. Lastly, it also attempts to provide possible future scenarios of high-intensive care that could improve patient outcomes.</p>","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"1065-1077"},"PeriodicalIF":4.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Heart Failure Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1